Minoxidil vs. Finasteride vs. Clascoterone: Which Hair Loss Treatment Is Right for You?

For decades, hair loss treatment was a two-horse race: minoxidil or finasteride. In 2026, a third contender — clascoterone — is poised to enter the market with Phase 3 data that's turning heads across dermatology. For the first time in 30 years, men have a genuinely new option.

But more choices means more confusion. This article breaks down all three treatments side by side — how they work, how effective they are, what the side effects look like, and who each one is best suited for.

How Each One Works

Minoxidil (Rogaine) doesn't address the hormonal cause of hair loss at all. It's a vasodilator — it increases blood flow to the scalp, which extends the growth phase of the hair cycle and may enlarge miniaturized follicles. Nobody fully understands its mechanism in hair growth; it was originally a blood pressure drug.

Finasteride (Propecia) targets the root cause. It blocks the enzyme (5-alpha reductase) that converts testosterone to DHT — the hormone responsible for follicle miniaturization. It reduces systemic DHT by about 70%.

Clascoterone (pending FDA approval) also targets DHT, but through a different mechanism. Instead of reducing DHT production body-wide, it blocks DHT from binding to the follicle receptor directly at the scalp. It's a topical androgen receptor inhibitor — applied to the scalp, stays at the scalp.

Efficacy Comparison

Minoxidil: Slows hair loss in roughly 60% of users. Regrowth is modest — most men see stabilization with some thickening rather than dramatic regrowth. Results take 3–6 months and require continuous use; stopping means losing gains within a few months.

Finasteride: The most proven efficacy of any current treatment. In clinical trials, 83% of men maintained or increased hair count over 2 years, with 90% showing visible improvement at 5 years. It both halts loss and drives meaningful regrowth. Results build over 6–24 months.

Clascoterone: Phase 3 trials (1,465 men) showed up to 539% relative improvement in target area hair count vs. placebo in one trial and 168% in the second. Patient-reported outcomes confirmed men perceived the difference themselves. Results were measurable at 6 months with continued improvement during the extension phase.

Side Effect Profiles

This is where the three treatments diverge most meaningfully:

Minoxidil: Generally well-tolerated. Common side effects are local — scalp irritation, dryness, flaking (especially with alcohol-based formulations). Systemic side effects are rare but can include headache and dizziness. No sexual side effects. The foam formulation tends to cause less irritation than the liquid.

Finasteride (oral): Sexual side effects reported in 1.5–4% of users (depending on study and nocebo contribution) — decreased libido, erectile changes, ejaculate volume reduction. Nocebo studies show expectation drives a significant portion of reported effects. Most side effects resolve during or after treatment. Rare reports of persistent effects (Post-Finasteride Syndrome) remain debated in the literature.

Clascoterone: In Phase 3 trials, side effects were comparable to the placebo group. No sexual side effects were reported. Minimal systemic absorption was detected. The safety profile is consistent with what you'd expect from a drug that stays local rather than entering the bloodstream.

Sources: Merck Phase 3 data; Cosmo Pharmaceuticals; JAAD; Dermatology Times

Practical Comparison

Form and application:

• Minoxidil: Topical liquid or foam, applied twice daily (some once-daily formulations available)
• Finasteride: One pill daily (oral) or topical solution applied daily (compounded, not FDA-approved)
• Clascoterone: Topical solution applied to the scalp (specific regimen TBD pending approval)

Availability:

• Minoxidil: Over the counter. No prescription needed. Available everywhere.
• Finasteride (oral): Prescription required. Generic available. Widely accessible.
• Finasteride (topical): Available through compounding pharmacies and telehealth. Not FDA-approved as standalone.
• Clascoterone: Not yet available. FDA submission expected 2026. Potential market entry late 2026 or 2027.

Cost:

• Minoxidil: $10–30/month (OTC)
• Finasteride (oral, generic): $5–15/month
• Finasteride (topical, compounded): $30–80/month
• Clascoterone: Pricing TBD (likely prescription-tier)

Time to see results:

• Minoxidil: 3–6 months for initial effect
• Finasteride: 3–6 months for initial effect, continues improving up to 24 months
• Clascoterone: 6 months in trials, with continued improvement beyond

Who Is Each Treatment Best For?

Minoxidil is best if you:

• Want an over-the-counter option with no prescription
• Are mainly looking to slow loss rather than reverse it
• Want to avoid any hormonal intervention
• Are supplementing finasteride or clascoterone for additional benefit

Oral finasteride is best if you:

• Want the strongest proven treatment available today
• Are comfortable with the (low) sexual side effect risk
• Prefer a once-daily pill over topical application
• Want the most cost-effective option

Topical finasteride is best if you:

• Want finasteride's efficacy with lower systemic exposure
• Are specifically concerned about sexual side effects from oral
• Don't mind daily scalp application
• Can access a compounding pharmacy or telehealth provider

Clascoterone is best if you (once available):

• Want DHT-targeted treatment with zero reported sexual side effects
• Have avoided finasteride specifically because of the side effect profile
• Prefer a topical-only approach
• Are willing to try a newer treatment with less long-term data

Can You Combine Them?

Yes — and many dermatologists recommend it. Minoxidil and finasteride work through completely different mechanisms, so combining them often produces better results than either alone. The same logic should apply to minoxidil plus clascoterone once it's available.

Combining oral finasteride with clascoterone is less clear-cut since both target DHT (through different mechanisms). Your dermatologist can advise on whether dual DHT blockade makes sense for your situation.

The Bottom Line

For the first time since 1997, the hair loss treatment landscape is genuinely expanding. Minoxidil remains the accessible, low-risk starting point. Finasteride remains the efficacy gold standard. And clascoterone is arriving with the potential to offer DHT-level effectiveness without the side effect profile that's kept millions of men on the sidelines.

The best treatment is the one that matches your priorities — whether that's maximum efficacy, minimum risk, lowest cost, or greatest convenience. A dermatologist can help you match the options to your specific hair loss pattern, health profile, and goals.

Your hair has more options than it's had in three decades. That's worth a conversation.

This article is for informational purposes only and is not medical advice. Consult a dermatologist for personalized treatment guidance.